Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812870 | 0.90 | EPHX2 (0.43) | EPHX2MCHR1MTORTBXA2RPTGDR | |
| SCHEMBL2816965 | 0.89 | EPHX2 (0.53) | EPHX2MTORNAMPTTBXA2RPTGDR | |
| SCHEMBL2819274 | 0.89 | EPHX2 (0.43) | EPHX2MCHR1MTORNAMPTTBXA2R | |
| SCHEMBL2817947 | 0.88 | HIF1A (0.48) | EPHX2NAMPTTBXA2RPTGDRPTGDR2 | |
| SCHEMBL2813899 | 0.87 | EPHX2 (0.46) | EPHX2MTORNAMPTPTGS1CA1 | |
| SCHEMBL2813822 | 0.87 | MAPT (0.43) | EPHX2MCHR1MTORNAMPTTBXA2R | |
| SCHEMBL2816640 | 0.86 | EPHX2 (0.45) | EPHX2MTORNAMPTCA1CA2 | |
| SCHEMBL2813625 | 0.85 | KMT2A (0.46) | NAMPTCA2 | |
| SCHEMBL2815905 | 0.85 | TBXA2R (0.42) | EPHX2MCHR1MTORNAMPTTBXA2R | |
| SCHEMBL2816401 | 0.84 | EPHX2 (0.42) | EPHX2MCHR1NAMPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | EPHX2 2238/4885MCHR1 4238/4885MTOR 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.